Royalty Report: Drugs, Disease, Alzheimer’s disease – Collection: 279383

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Alzheimer’s disease
  • Nerve
  • Diagnostic
  • Stroke treatment
  • cardiac
  • Cancer
  • Drug Discovery
  • Central Nervous System
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279383

License Grant
The Israeli Licensor grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under the Licensed Technology and Research Technology to research, develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products and Additional Products in the Field.
License Property
The research is for Novel compounds for treatment and as Disease-modifying agents in alzheimers and related CNS & PNS Diseases.

The patents relate to AF150(S) and Congeners, and, AF267B and Congeners, and, AF292 and Congeners.

Licensed Compound shall mean the compound known as AF292 and its isomers, salts, esters and derivatives.

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The peripheral nervous system (PNS) is one of two components that make up the nervous system of bilateral animals, with the other part being the central nervous system (CNS).

Field of Use
The Field shall mean all therapeutic uses.  The compounds for patented drugs are for treatment, prevention and/or diagnosis of nervous system disorders.

License relates to muscarinic agonist assets including its lead drug candidate for Alzheimer’s Disease, or AD, NGX267, and NGX292.

IPSCIO Record ID: 269747

License Grant
The University has granted a world-wide right and exclusive license, with the right to grant sublicenses, under certain patent rights and related technology.
License Property
The licensed property is for the use of bryostatin structural derivatives, known as bryologs.

Bryostatin is a drug targeting the activation of Protein Kinase C epsilon.

Field of Use
This license is for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury.  Bryostatin is used for the treatment of Alzheimer’s disease.

IPSCIO Record ID: 266151

License Grant
The Company entered into a Research Grant and License Agreement with an Undisclosed Stockholder of the Company. The Agreement requires the Company to pay royalties to the stockholder.
License Property
The Company’s lead compound, COR388, is beginning Phase 2/3 development, targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models.  The compound is being developed for treatment of Alzheimers Disease.
Field of Use
This agreement pertains to the drug industry.  The IP will be used to try and create a disease-modifying therapeutic approach to Alzheimer’s and other degenerative diseases.

IPSCIO Record ID: 371879

License Grant
Licensor in-licensed to Licensee the exclusive worldwide rights to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111.
License Property
2X-111 is an advanced, targeted liposomal formulation of Doxorubicin, one of the world’s most widely used chemotherapies. The specific 2X-111 formulation, which exploits a glutathione enhanced PEG-liposomal delivery system, may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, which is necessary for DNA replication. Topo isomerase 2 is an enzyme that cuts both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils.

Preclinical studies have been performed in order to determine the anti-cancer activity and toleration of 2X-111 both systemically and in the CNS prior to the start of the human clinical trials.

Field of Use
Field of use is for treatment of peripheral effects of agents causing CNS (central nervous system) disease or symptoms, including Cancer.

The right is  to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111

The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord.

Cerebrovascular disease refers to a group of conditions, diseases, and disorders that affect the blood vessels and blood supply to the brain. If a blockage, malformation, or hemorrhage prevents the brain cells from getting enough oxygen, brain damage can result.

Licensee believes may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

IPSCIO Record ID: 239026

License Grant
For selected targets, Licensor grants to Licensee and its Affiliates, within the Territory, a non-exclusive right and license, without any right to sublicense, except as set forth below,  under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and a co-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to identify and validate Selected Targets, other than Selected Targets that have become Licensee Inactive Selected Targets, Licensor Inactive Selected Targets, Licensee Targets or Licensor Targets, for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field,  identify Small Molecule Compounds that are active against such Selected Targets through the use of such Selected Targets and undertake preclinical research and evaluation of Program Compounds, in each case in the conduct of the Research Program.

For the Inactive Selective Targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below,  under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to validate Licensee Inactive Selected Targets for the identification, evaluation and optimization of Small Molecule Compounds that are active against such Selected Targets for use in the CNS Field,  identify Small Molecule Compounds that are active against such Licensee Inactive Selected Targets through the use of such Licensee Inactive Selected Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Inactive Selected Targets.

For the Licensee targets, Licensor grants to Licensee and its Affiliates, within the Territory,  a non-exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Licensor Background Materials and the Licensor Background Technology and an exclusive right and license, without any right to sublicense, except as set forth below, under Licensors rights in the Program Intellectual Property to identify Small Molecule Compounds that are active against Licensee Targets through the use of such Licensee Targets and undertake preclinical research and evaluation of Small Molecule Compounds that are active against such Licensee Targets.

For the Grants of Development and Commercialization Licenses, Licensor grants to Licensee and its Affiliates, within the Territory, an exclusive right and license, with the right to sublicense, under Licensors rights in the Program Intellectual Property to develop, make, have made, import, use, have used, offer for sale, sell and have sold Licensee Development Compounds and Licensee Products.

License Property
Licensor is engaged in the identification and validation of targets for use in the discovery of compounds potentially useful to prevent or treat diseases and conditions of the central nervous system.

Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, as well as conjugates of such chemical compounds to larger molecules to improve the delivery bioavailability and/or pharmacokinetic properties of such chemical compound.

Licensors Product means a pharmaceutical product containing a Licensor Development Compound as an active ingredient.

Selected Target means any Target that is selected for research by the Joint Management Committee.

Field of Use
Both Parties are each in the business of discovering, developing and commercializing pharmaceutical products.

CNS Field means the prevention, palliation, control or treatment in humans of depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit hyperactivity disorder, anorexia nervosa and other affective disorders, Alzheimers disease and other cognitive disorders, Parkinsons disease, amyotrophic lateral sclerosis and other neurodegenerative disorders, pain, epilepsy, insomnia, narcolepsy and other sleep disorders, substance abuse and migraine.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.